Literature DB >> 10783309

Cell activation via CD44 occurs in advanced stages of squamous cell carcinogenesis.

S Bruno1, M Fabbi, M Tiso, B Santamaria, F Ghiotto, D Saverino, C Tenca, D Zarcone, S Ferrini, E Ciccone, C E Grossi.   

Abstract

Squamous cell carcinoma (SCC) derives from dysplastic or metaplastic stratified epithelia. The process of squamous cell carcinogenesis has been investigated for the potential role of the adhesion molecule CD44, whose standard form (CD44s) and isoforms generated by alternative splicing of variant exons are known to display altered expression during tumorigenesis in other systems. We have utilized an in vitro correlate of squamous cell carcinogenesis, in which progression stages from normal squamous epithelium to dysplastic lesions and to SCC are represented by primary cultures of normal keratinocytes, by human papilloma virus-immortalized keratinocytes (UP) and by HPVimmortalized/v-Ha-ras transfected tumorigenic keratinocytes (UPR). We investigated expression of CD44 and of variant isoforms, from mRNA to intracellular and surface protein levels, and found no relationship between expression of CD44 and stages of squamous cell carcinogenesis. However, when the function of CD44 was analyzed as Ca(2+) mobilization ability upon monoclonal antibody binding and crosslinking, signal transduction via CD44 was found only for the neoplastic stage (UPR cells). Ca(2+) mobilization was completely independent of density of surface CD44. We have performed similar analyses in an in vitro model of SCC in which four squamous tumor cell lines and UPR cells were sorted according to increasing resistance to external cytotoxic stimuli, i.e. starving conditions, treatment with the retinoid N-(4-hydroxyphenyl)retinamide and cytolytic activity of effector lymphokine-activated killer cells. No relationship between expression of CD44 and level of cell resistance against external cell death-inducing stimuli was found, while CD44-mediated Ca(2+) mobilization ability was restricted to the highly resistant tumor cell lines. Our results indicate that the role(s) of CD44 in squamous cell proliferative disorders can be evinced from the functional features of the molecule, rather than from its phenotypic repertoire.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783309     DOI: 10.1093/carcin/21.5.893

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  4 in total

1.  Prognostic significance of CD44s expression in resected non-small cell lung cancer.

Authors:  Yoon Ho Ko; Hye Sung Won; Eun Kyoung Jeon; Sook Hee Hong; Sang Young Roh; Young Seon Hong; Jae Ho Byun; Chan-Kwon Jung; Jin Hyoung Kang
Journal:  BMC Cancer       Date:  2011-08-07       Impact factor: 4.430

2.  Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.

Authors:  Kazue Masuko; Shogo Okazaki; Mayumi Satoh; Goh Tanaka; Tatsuya Ikeda; Ryota Torii; Eri Ueda; Takashi Nakano; Masaaki Danbayashi; Tomoyo Tsuruoka; Yoshiya Ohno; Hideki Yagi; Noritsugu Yabe; Hideaki Yoshida; Tomoyuki Tahara; Shiro Kataoka; Taichi Oshino; Takayuki Shindo; Shin-ichiro Niwa; Takatsugu Ishimoto; Hideo Baba; Yoshiyuki Hashimoto; Hideyuki Saya; Takashi Masuko
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

3.  Characterization of CD44 variant expression in head and neck squamous cell carcinomas.

Authors:  D Spiegelberg; G Kuku; R Selvaraju; M Nestor
Journal:  Tumour Biol       Date:  2014-03

4.  Fluorescence and electron microscopy to visualize the intracellular fate of nanoparticles for drug delivery.

Authors:  M Costanzo; F Carton; A Marengo; G Berlier; B Stella; S Arpicco; M Malatesta
Journal:  Eur J Histochem       Date:  2016-04-14       Impact factor: 3.188

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.